Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05794477 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Start date: April 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.

NCT ID: NCT05791474 Withdrawn - Clinical trials for Advanced Solid Tumor

ATI-2231 in Advanced Solid Tumor Malignancies

Start date: November 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

NCT ID: NCT05790447 Recruiting - Clinical trials for Advanced Solid Tumor

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of precise thymalfasin-regulated therapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF for treatment of advanced refractory solid tumors.

NCT ID: NCT05789602 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of BPI-460372 in Advanced Solid Tumor Patients

Start date: April 24, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.

NCT ID: NCT05785741 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Start date: April 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

NCT ID: NCT05785728 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of DB-1202 Monotherapy in Advanced Solid Tumors

Start date: June 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1201 in subjects with advanced solid tumors.

NCT ID: NCT05781386 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

Start date: March 6, 2022
Phase: Phase 1
Study type: Interventional

This is a first in human, open-label, dose escalation and expansion Phase I study of SIM1811-03 in adult patients with advanced tumors. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.

NCT ID: NCT05780307 Recruiting - Breast Cancer Clinical Trials

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Start date: March 23, 2023
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.

NCT ID: NCT05772455 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of XZB-0004 in Patients With Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL. This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors. Part 1 is a dose-escalation study to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic profile of XZB-0004, and then to identify a safe and pharmacologically active dose for evaluation in subsequent cohorts or clinical studies. Part 2 is a study to evaluate the efficacy and safety of XZB-0004 combined with Peamplimab in patients with NSCLC or advanced solid tumors.

NCT ID: NCT05768932 Recruiting - Clinical trials for Advanced Solid Tumor

BAL0891 in Patients With Advanced Solid Tumors

Start date: December 14, 2022
Phase: Phase 1
Study type: Interventional

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with carboplatin or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors.